Neurotransmitters and CNS disease. Schizophrenia.
D014150:Antipsychotic Agents / Q000494:pharmacology / Q000627:therapeutic use; D001284:Atrophy; D001921:Brain / Q000378:metabolism / Q000473:pathology; D002552:Cerebral Ventricles / Q000473:pathology; D002908:Chronic Disease; D004298:Dopamine / Q000009:adverse effects / Q000502:physiology* / Q000627:therapeutic use; D004723:Endorphins / Q000627:therapeutic use; D018756:GABA Antagonists; D006801:Humans; D008995:Monoamine Oxidase / Q000502:physiology; D009270:Naloxone / Q000494:pharmacology; D018377:Neurotransmitter Agents / Q000502:physiology* / Q000627:therapeutic use; D011954:Receptors, Dopamine / Q000187:drug effects / Q000502:physiology; D012559:Schizophrenia / Q000145:classification / Q000188:drug therapy / Q000209:etiology* / Q000503:physiopathology; D005680:gamma-Aminobutyric Acid / Q000627:therapeutic use
D014150:Antipsychotic Agents; D004723:Endorphins; D018756:GABA Antagonists; D018377:Neurotransmitter Agents; D011954:Receptors, Dopamine; D009270:Naloxone; D005680:gamma-Aminobutyric Acid; D008995:Monoamine Oxidase; D004298:Dopamine